TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07581431: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of ISM8969 in Healthy Adult and Elder

Sponsor: InSilico Medicine Hong Kong Limited · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07581431 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07581431 Rescue Dossier →